Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 1, 2015Molecular Cancer Therapeutics

AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML

View Full Paper
Ask AI
Bookmark
Share

Authors

DPDaniel S. PereiraBrazilian Agricultural Research CorporationCGClaudia GuevaraKite (United States)LJLiqing JinUniversity Health Network

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Pereira et al. (2015) studied this question.

synapsesocial.com/papers/6a72764822b3175134db762fhttps://doi.org/10.1158/1535-7163.mct-15-0067
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies2013 · 95 citations
  2. 2Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer2012 · 3,869 citations
  3. 3Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice2014 · 464 citations
  4. 4A unique antigen on mature B cells defined by a monoclonal antibody.1986 · 51 citations
  5. 5Use of the monoclonal antibody WR17, identifying the CD37 gp40–45 Kd antigen complex, in the diagnosis of B‐lymphoid malignancy1987 · 46 citations